Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Systemic anti-cancer therapy (SACT) for adults with relapsed or refractory chronic lymphocytic leukaemia who have been previously treated with a Bruton's tyrosine kinase inhibitor (BTKi): SMC2901

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Pirtobrutinib for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL) who have been previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi) (SMC2901) is being assessed for use by NHS Scotland.

The aim of this work was to capture real-world evidence (RWE) from Scotland on the treatment of adults with R/R CLL who have been previously treated with a BTKi. Details of the presumptions made to identify this cohort are described in Section 2.3.1 in the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2901, to patients in Scotland.

The objectives were to:

• Determine the number of patients receiving systemic anti-cancer therapy (SACT) for the treatment of R/R CLL who have been previously treated with a BTKi.
• Describe the baseline characteristics of patients receiving SACT for the treatment of R/R CLL who have been previously treated with a BTKi.
• Describe the SACT regimens prescribed for patients with R/R CLL who have been previously treated with a BTKi.
• Determine the number of patients receiving SACT for the treatment of R/R CLL who have been previously treated with both a BTKi and a B-cell lymphoma 2 (BCL-2) inhibitor.